FDA Introduces Strategy to Combat Food Smuggling - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Introduces Strategy to Combat Food Smuggling


ePT--the Electronic Newsletter of Pharmaceutical Technology

In early July 2011, FDA provided an update in which the agency said that it has made progress toward implementing the US Food Safety Modernization Act (FSMA), which was enacted in January 2011. In addition to clarifying expectations for new dietary ingredients through new draft guidance, the agency has issued an antismuggling strategy.

FDA worked with the US Department of Homeland Security to create the strategy, which aims to “identify and prevent smuggled foods from entering the United States and posing a threat to national security and consumer safety,” according to an agency press release. Although the strategy, like many portions of FSMA, focuses on food safety, many components and directives within the act also pertain to pharmaceuticals. Food-safety actions taken now may provide guidance for drug-safety issues in the future (see “FDA Gains Food Recall Authority, Drugs Could be Next”).

“This new system, overall, will better leverage the resources of federal agencies and it will make industry an important partner in safeguarding the health of US consumers,” said Deputy Commissioner for Foods Michael R. Taylor in the press release.

As part of the strategy, FDA will work with US Customs and Border Protection (CBP) to review historical data and better identify products, firms, and countries of origin to target potential food smuggling and smugglers. FDA and CBP also will share information on import shipments and conduct joint examinations to identify shipments that may contain smuggled food. FDA has been increasing its focus on drug imports at the borders as well with its Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting (PREDICT) computer system and its new spectral library system aimed at identifying excipients.

The agency also issued draft guidance regarding new dietary ingredients as part of FSMA implementation. The document aims to prevent consumers from being exposed to “unnecessary public-health risks from new ingredients with unknown safety profiles,” says the press release. Specifically, dietary-supplement manufacturers are required to notify FDA before adding a new dietary ingredient to their products, except when the ingredient has been part of the food supply and has not been chemically altered for use in supplements.

FDA has a website devoted to FSMA implementation and updates for more information.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here